The Neostigmine Methylsulfate Injection is the first manufacturer-prepared, ready-to-administer prefilled syringe on the market.
The Neostigmine Methylsulfate Injection, USP in 3 mg per 3 ml, has just been released in ready-to-administer prefilled syringes through Fresenius Kabi, which specializes in medicines and technologies for infusion, transfusion, and clinical nutrition. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents (NMBA) after surgery.
The first manufacturer-prepared, ready-to-administer prefilled syringe on the market, the Fresenius Kabi Simplist Neostigmine Injection, USP has also been sold in 0.5 mg per 1 ml and 1 mg per 1 ml vial presentations since 2015.
According to a previous Pharmacy Times article, the Neostigmine Methylsulfate Injection, USP is a sterile, nonpyrogenic solution intended for intramuscular, subcutaneous, or slow intravenous use. Dosing is highly individualized and is determined based on the half-life of the NMBA being reversed, the extent of recovery that has already occurred prior to administration, and whether there is a need to rapidly reverse the NMBA effects.
“Fresenius Kabi is pleased to continue the expansion of our convenient Simplist prefilled syringe portfolio,” said John Ducker, president and CEO of Fresenius Kabi. “This is the fourth Simplist product we’ve introduced this year and represents the strength of our pipeline of important therapies and delivery systems that can help physicians practice more efficiently.”